Neurology: Neuroimmunology & Neuroinflammation
Articles on COVID-19 and Multiple Sclerosis
Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis
Gertjan Peeters, Ann Van Remoortel, Guy Nagels, Jeroen Van Schependom, Miguel D'haeseleer
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year
Giulio Disanto, Alice Galante, Marco Cantu', et al.
Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment
Christina Woopen, Marie Dunsche, Rocco Haase, et al.
Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity
Steve Simpson-Yap, Ashkan Pirmani, Tomas Kalincik, et al.
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis
Ana Zabalza, Georgina Arrambide, Paula Tagliani, et al.
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study
Pietro Iaffaldano, Giuseppe Lucisano, Alessia Manni, et al.
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
Roseanne Sullivan, Ajay Kilaru, Bernhard Hemmer, et al.
Recovery From COVID-19 in Multiple Sclerosis: A Prospective and Longitudinal Cohort Study of the United Kingdom Multiple Sclerosis Register
Afagh Garjani, Rodden M. Middleton, Richard Nicholas, Nikos Evangelou
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
Martin S. Weber, Jacqueline A. Nicholas, Michael R. Yeaman
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context
Maria Pia Sormani, Irene Schiavetti, Luca Carmisciano, et al.
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies: An Observational Study
Kévin Bigaut, Laurent Kremer, Thibaut Fabacher, et al.
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry
Georgina Arrambide, Miguel Ángel Llaneza-González, Lucienne Costa-Frossard França, et al.
COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review
Mahdi Barzegar, Omid Mirmosayyeb, Mahsa Gajarzadeh, et al.
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
Farren Basil Shaw Briggs, Farrah J. Mateen, Hollie Schmidt, et al.
Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
Lara Diem, Christoph Friedli, Andrew Chan, Anke Salmen, Robert Hoepner
Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit
Maria Sepúlveda, Sara Llufriu, Eugenia Martínez-Hernández, et al.
Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19
Vidmante Fuchs, Michael Kutza, Sven Wischnewski, et al.
COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center
Erica Parrotta, Ilya Kister, Leigh Charvet, et al.
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Adil Maarouf, Audrey Rico, Clemence Boutiere, Marine Perriguey, Sarah Demortiere, Jean Pelletier, Bertrand Audoin, Under the aegis of OFSEP
Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
Cole Maguire, Teresa Frohman, Scott S. Zamvil, Elliot Frohman, Esther Melamed
COVID-19 in MS: Initial observations from the Pacific Northwest
James D. Bowen, Justine Brink, Ted R. Brown, Elisabeth B. Lucassen, Kyle Smoot, Annette Wundes, Pavle Repovic
COVID-19 and MS Disease-modifying Therapies
Joseph R. Berger, Rachel Brandstadter, Amit Bar-Or
COVID-19 Infection in a Patient With Multiple Sclerosis Treated With Fingolimod
Mahdi Barzegar, Omid Mirmosayyeb, Nasim Nehzat, et al.
